Aandeel ONCOLYTICS BIOTECH INC.
Toevoegen aan een lijst
Om deze functie te gebruiken moet u een klant of lid zijn.
InloggenRegistreren
Inactief instrument

Andere talen Oncolytics Biotech Inc. Nasdaq

Aandelen

CA6823101077

Andere talen

Zoeken op
Resultaten bekijken
Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!
Gratis inschrijven
RBC on Oncolytics Biotech's Upcoming Type C Meeting With FDA
Oncolytics Biotech Receives Regulatory Clearance to Evaluate Pelareorep in Combination with Modified FOLFIRINOX +/- an anti-PD-L1 Inhibitor in Pancreatic Cancer
Oncolytics Biotech Reports a First-Quarter Loss of Near $7 Million
Oncolytics Biotech Brief: Q1 Basic and diluted loss per common share $0.09
Oncolytics Biotech® Reports First Quarter 2024 Financial Results and Operational Highlights
Oncolytics Biotech Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
Oncolytics Biotech Receives German Regulatory Clearance to Evaluate Pelareorep with Modified Folfirinox in Pancreatic Cancer
Oncolytics Biotech Brief: Says Received Regulatory Clearance to Evaluate Pelareorep in Combination with Modified FOLFIRINOX +/- an anti-PD-L1 Inhibitor in Pancreatic Cancer
Oncolytics Biotech® Inc. Receives Regulatory Clearance to Evaluate Pelareorep in Combination with Modified FOLFIRINOX+/- an Anti-PD-L1 Inhibitor in Pancreatic Cancer
Oncolytics Biotech® to Participate in a Fireside Chat at the 2024 RBC Capital Markets Global Healthcare Conference
Oncolytics Biotech to Host Conference Call to Discuss First Quarter Financial Results and Recent Operational Highlights
Oncolytics Biotech® to Host Conference Call to Discuss First Quarter Financial Results and Recent Operational Highlights
Oncolytics Biotech Announces Upcoming Presentations at the American Society of Clinical Oncology Annual Meeting
Oncolytics Biotech® Announces Upcoming Presentations at the American Society of Clinical Oncology Annual Meeting
Oncolytics Biotech : NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON MAY 15, 2024 MANAGEMENT INFORMATION CIRCULAR - Form 6-K
Oncolytics Biotech Advances toward Registration-Enabling Trial for Pelareorep in Breast Cancer with Submission of Type C Meeting Request to FDA
Oncolytics Biotech Inc. Announces the Submission of a Type C Meeting Request to the FDA
Oncolytics Biotech Down 1.8% In US Premarket As Submits Type C Meeting Request to FDA
Oncolytics Biotech Brief: Advancing Toward Registration-Enabling Trial for Pelareorep in Breast Cancer with Submission of Type C Meeting Request to FDA
Oncolytics Biotech® Advances Toward Registration-Enabling Trial for Pelareorep in Breast Cancer with Submission of Type C Meeting Request to FDA
Geen resultaten voor deze zoekopdracht
Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Filters

Zoeken op

Datum van publicatie

Sinds de

Tot

  1. Beurs
  2. Aandelen
  3. Koers ONC
  4. Koers
  5. Nieuws Oncolytics Biotech Inc.
  6. Andere talen